Ignite Creation Date:
2024-05-06 @ 8:12 PM
Last Modification Date:
2024-10-26 @ 3:23 PM
Study NCT ID:
NCT06297564
Status:
COMPLETED
Last Update Posted:
2024-03-07
First Post:
2024-02-22
Brief Title:
Progesterone Primed Endometrial Protocol Versus Gonadotropin-releasing Hormone Antagonist Protocol in Assisted Reproductive Treatments
Sponsor:
New Valley University
Organization:
New Valley University
Study Overview
Official Title:
Progesterone Primed Endometrial Protocol Versus Gonadotropin-releasing Hormone Antagonist Protocol in Women Undergoing Assisted Reproductive Treatments
Status:
COMPLETED
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The aim of this study was to compare the clinical outcomes in progesterone primed endometrial protocol versus gonadotropin-releasing hormone antagonist protocol in women undergoing assisted reproductive treatments
Detailed Description:
Utilizing the assisted reproductive techniques ART has exhibited a substantial rise within the last years emerging as a crucial modern medicine component with reliable results
The utilized protocols for endometrial preparation in ART are aimed at maximizing the treatments success Typically utilizing gonadotropin-stimulating hormone GnRH antagonists or agonists remains involved for preventing an early luteinizing hormone LH peak along ovulation prior to oocytes retrieval
The GnRH-antagonist GnRH-a protocol is favored by many clinicians as well as patients due to its simplicity convenience flexibility and absence of functional ovarian cysts or menopausal symptoms linked to the agonist protocol Nevertheless some RCTs findings address that the antagonist protocol yields a reduced oocytes number Additionally it exhibits lower pregnancy rates as opposed to the agonist extended therapy
The utilized protocols for endometrial preparation in ART are aimed at maximizing the treatments success Typically utilizing gonadotropin-stimulating hormone GnRH antagonists or agonists remains involved for preventing an early luteinizing hormone LH peak along ovulation prior to oocytes retrieval
The GnRH-antagonist GnRH-a protocol is favored by many clinicians as well as patients due to its simplicity convenience flexibility and absence of functional ovarian cysts or menopausal symptoms linked to the agonist protocol Nevertheless some RCTs findings address that the antagonist protocol yields a reduced oocytes number Additionally it exhibits lower pregnancy rates as opposed to the agonist extended therapy
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None